A randomized trial of the Low-Molecular-Weight Heparin certoparin to prevent restenosis following coronary angioplasty

Journal of Invasive Cardiology

Volumn 13, Issue 11, 2001, Pages 723-728

  Grassman, Eric D ^a   Leya, Fred ^a   Fareed, Jawed ^a   Lewis, Bruce E ^a   Bacher, Peter ^a   Loeb, Henry S ^b   Moran, John F ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Hines Veteran's Administration Center   (United States)

^c Midwest Heart Institute   (United States)

Author keywords

Angioplasty; Heparin; PARAT trial; Restenosis

Indexed keywords

ANTICOAGULANT AGENT; CERTOPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DOUBLE BLIND PROCEDURE; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 0035514422     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Serruys PW, Luisten HE, Beat KJ, et al. Incidence of restenosis after successful coronary angioplasty: A time related phenomenon. Circulation 1988;77:361-371.
2. Nobuyoshi M, Taheshi K, Nosaka H, et al. Restenosis after successful PTCA: Serial angiographic follow up of 229 patients. J Am Coll Cardiol 1988;12:616-623.
3. Holmes DR Jr., Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984;53:77C-81C.
4. Castellot J, Wong K, Herman B, et al. Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 1985;124:13-20.
5. Currier JW, Pow TK, Haudenschild CC, et al. Low molecular weight heparin (enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbits. J Am Coll Cardiol 1991;17:118B-125B.
6. Strecker EP, Gottmann D, Boos IB, Vetter S. Low-molecular-weight heparin (reviparin) reduces the incidence of femoropopliteal in-stent stenosis: Preliminary results of an ongoing study. Cardiovasc Intervent Radiol 1998;21:375-379.
7. Hoover R, Rosenburg R, Hearing W, Karnowsky M. Inhibition of rat arterial smooth muscle cell proliferation by heparin: Two in vitro studies. Circ Res 1980;47:578-583.
8. Guyton J, Rosenburg R, Clowes A, Karnowsky M. Inhibition of rate arterial smooth muscle cell proliferation by heparin: In vivo studies with anticoagulant and non-anticoagulant heparin. Circ Res 1980;46:625-634.
9. Hermans WR, Rensing BJ, Kelder JC, et al. Postangioplasty restenosis rate between segments of the major coronary arteries. Am J Cardiol 1992;69:194-200.
10. Beauman GJ, Reiber JH, Koning G, et al. Comparisons of angiographic core laboratory analyses of phantom clinical images: Interlaboratory variability. Cathet Cardiovasc Diagn 1996;37:24-31.
11. Taylor RR, Gibbons FA, Cope GD, et al. Effects of low dose aspirin on restenosis after coronary angioplasty. Am J Cardiol 1991;68:874-878.
12. Ellis SG, Roubin GS, Wilentz J, et al. Effect of 18-24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-782.
13. Faxon DP, Spiro TE, Minor S, et al., for the ERA Investigators. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial. Circulation 1994;90:908-914.
14. Caims JA, Gill J, Morton B, et al., for the EMPAR Collaborators. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Circulation 1996;94:1553-1560.
15. Karsch KR, Preisack ML, Baildon R, et al. Low-molecular-weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE). J Am Coll Cardiol 1996;28:1437-1443.
16. Lablanche JM, McFadden EP, Meneveau N, et al. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: The FACT study. Fraxiparin Angioplastie Coronaire Transluminale. Circulation 1997;96:3396-3402.
17. Serruys PW, Herrman JPR, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-763.
18. Dehmer GJ, Popma JJ, van den Berg EK, et al. Reduction in the rate of early stenosis after coronary angioplasty by a diet supplemented with omega-3 fatty acids. N Engl J Med 1988;319:733-740.
19. Tardiff JC, Coté G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty: Multivitamins and the Probucol study group. N Engl J Med 1996;337:365-372.
20. Teirstein PS, Massullo V, Jani S, et al. Catheter based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997;336:1697-1703.
21. Crocker I, Popma J, Suntharalingham M, et al. Endovascular beta radiation is effective in the management of coronary in-stent restenosis: Results of the stents and radiation therapy trial (START). Radiother Oucol 2000;56(Suppl 1):S46.